These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 39038086)
1. Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome. Valgimigli M; Landi A; Angiolillo DJ; Baber U; Bhatt DL; Bonaca MP; Capodanno D; Cohen DJ; Gibson CM; James S; Kimura T; Lopes RD; Mehta SR; Montalescot G; Sibbing D; Steg PG; Stone GW; Storey RF; Vranckx P; Windecker S; Mehran R Circulation; 2024 Jul; 150(4):317-335. PubMed ID: 39038086 [TBL] [Abstract][Full Text] [Related]
2. De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis. De Filippo O; Piroli F; Bruno F; Bocchino PP; Saglietto A; Franchin L; Angelini F; Gallone G; Rizzello G; Ahmad M; Gasparini M; Chatterjee S; De Ferrari GM; D'Ascenzo F BMJ Evid Based Med; 2024 May; 29(3):171-186. PubMed ID: 38242567 [TBL] [Abstract][Full Text] [Related]
3. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233 [TBL] [Abstract][Full Text] [Related]
4. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial. Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541 [TBL] [Abstract][Full Text] [Related]
5. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S; Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT) in the UK: study protocol for three population-based cohort studies emulating 'target trials' (the ADAPTT Study). Pufulete M; Harris J; Sterne JAC; Johnson TW; Lasserson D; Mumford A; Doble B; Wordsworth S; Benedetto U; Rogers CA; Loke Y; Pithara C; Redwood S; Reeves BC BMJ Open; 2019 Jun; 9(6):e029388. PubMed ID: 31167875 [TBL] [Abstract][Full Text] [Related]
8. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Cuisset T; Deharo P; Quilici J; Johnson TW; Deffarges S; Bassez C; Bonnet G; Fourcade L; Mouret JP; Lambert M; Verdier V; Morange PE; Alessi MC; Bonnet JL Eur Heart J; 2017 Nov; 38(41):3070-3078. PubMed ID: 28510646 [TBL] [Abstract][Full Text] [Related]
9. Ticagrelor monotherapy after short duration of dual antiplatelet therapy compared to continued dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary interventions: an updated meta-analysis. Mansuri Z; Ashraf H; Taikadan T; Rajith G; Ayesha A; Fatima U; Erzinger G Coron Artery Dis; 2024 Nov; 35(7):590-597. PubMed ID: 39171570 [TBL] [Abstract][Full Text] [Related]
10. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials. Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261 [TBL] [Abstract][Full Text] [Related]
11. P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials. Song PS; Park YH; Oh JH; Song YB; Choi SH; Gwon HC; Cho DK; Rha SW; Bae JW; Jeong JO; Hahn JY; Am J Cardiol; 2021 Jul; 150():47-54. PubMed ID: 34011436 [TBL] [Abstract][Full Text] [Related]
12. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials. Valgimigli M; Hong SJ; Gragnano F; Chalkou K; Franzone A; da Costa BR; Baber U; Kim BK; Jang Y; Chen SL; Stone GW; Hahn JY; Windecker S; Gibson MC; Song YB; Ge Z; Vranckx P; Mehta S; Gwon HC; Lopes RD; Dangas GD; McFadden EP; Angiolillo DJ; Leonardi S; Heg D; Calabrò P; Jüni P; Mehran R; Hong MK; Lancet; 2024 Sep; 404(10456):937-948. PubMed ID: 39226909 [TBL] [Abstract][Full Text] [Related]
13. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial. Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S; Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610 [TBL] [Abstract][Full Text] [Related]
14. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Kim HS; Kang J; Hwang D; Han JK; Yang HM; Kang HJ; Koo BK; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Park KW; Lancet; 2020 Oct; 396(10257):1079-1089. PubMed ID: 32882163 [TBL] [Abstract][Full Text] [Related]
15. Antiplatelet Strategy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis. Ullah W; Sandhyavenu H; Taha A; Narayana Gowda S; Mukhtar M; Reddy Polam A; Zahid S; Fischman DL; Savage MP; Rao SV; Alkhouli M J Am Heart Assoc; 2024 Oct; 13(20):e032490. PubMed ID: 39392170 [TBL] [Abstract][Full Text] [Related]
16. Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'target trial'. Pufulete M; Harris J; Pouwels K; Reeves BC; Lasserson D; Loke YK; Mumford A; Mahadevan K; Johnson TW Open Heart; 2022 Aug; 9(2):. PubMed ID: 35961692 [TBL] [Abstract][Full Text] [Related]
17. Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials. Ray A; Najmi A; Khandelwal G; Jhaj R; Sadasivam B Cardiovasc Drugs Ther; 2021 Jun; 35(3):561-574. PubMed ID: 32816142 [TBL] [Abstract][Full Text] [Related]
18. An Aspirin-Free Strategy for Immediate Treatment Following Complex Percutaneous Coronary Intervention. Yamamoto K; Natsuaki M; Watanabe H; Morimoto T; Obayashi Y; Nishikawa R; Ando K; Suwa S; Isawa T; Takenaka H; Ishikawa T; Tamura T; Kawahatsu K; Hayashi F; Akao M; Serikawa T; Mori H; Kawamura T; Hagikura A; Shibata N; Ono K; Kimura T; JACC Cardiovasc Interv; 2024 May; 17(9):1119-1130. PubMed ID: 38749592 [TBL] [Abstract][Full Text] [Related]
19. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T; JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644 [TBL] [Abstract][Full Text] [Related]
20. Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT). Graham CA; Tan MK; Chew DP; Gale CP; Fox KAA; Bagai A; Henderson MA; Quraishi AUR; Déry JP; Cheema AN; Fisher H; Brieger D; Lutchmedial SR; Lavi S; Wong BYL; Cieza T; Mehta SR; Brass N; Goodman SG; Yan AT Heart Vessels; 2022 Aug; 37(8):1291-1298. PubMed ID: 35089380 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]